-$0.47 EPS Expected for Syros Pharmaceuticals Inc (NASDAQ:SYRS) This Quarter
Brokerages predict that Syros Pharmaceuticals Inc (NASDAQ:SYRS) will announce earnings per share of ($0.47) for the current quarter, according to Zacks Investment Research. Five analysts have made estimates for Syros Pharmaceuticals’ earnings, with the highest EPS estimate coming in at ($0.38) and the lowest estimate coming in at ($0.59). Syros Pharmaceuticals posted earnings per share of ($0.54) during the same quarter last year, which suggests a positive year over year growth rate of 13%. The business is scheduled to report its next earnings results on Thursday, March 5th.
According to Zacks, analysts expect that Syros Pharmaceuticals will report full-year earnings of ($1.88) per share for the current fiscal year, with EPS estimates ranging from ($2.01) to ($1.77). For the next year, analysts forecast that the business will report earnings of ($1.93) per share, with EPS estimates ranging from ($2.38) to ($1.56). Zacks’ EPS averages are a mean average based on a survey of research analysts that follow Syros Pharmaceuticals.
Syros Pharmaceuticals (NASDAQ:SYRS) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.47) EPS for the quarter, topping analysts’ consensus estimates of ($0.48) by $0.01. The business had revenue of $0.56 million for the quarter, compared to analysts’ expectations of $0.43 million. Syros Pharmaceuticals had a negative net margin of 3,115.38% and a negative return on equity of 84.49%.
A number of institutional investors have recently added to or reduced their stakes in the stock. Bank of Montreal Can grew its stake in Syros Pharmaceuticals by 44.6% in the 4th quarter. Bank of Montreal Can now owns 4,400 shares of the company’s stock valued at $30,000 after acquiring an additional 1,357 shares during the period. Bank of America Corp DE grew its stake in Syros Pharmaceuticals by 10.0% in the 4th quarter. Bank of America Corp DE now owns 15,081 shares of the company’s stock valued at $104,000 after acquiring an additional 1,366 shares during the period. Tower Research Capital LLC TRC grew its stake in Syros Pharmaceuticals by 863.4% in the 3rd quarter. Tower Research Capital LLC TRC now owns 2,688 shares of the company’s stock valued at $28,000 after acquiring an additional 2,409 shares during the period. Charles Schwab Investment Management Inc. grew its stake in Syros Pharmaceuticals by 3.1% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 205,350 shares of the company’s stock valued at $1,419,000 after acquiring an additional 6,256 shares during the period. Finally, Citigroup Inc. grew its stake in Syros Pharmaceuticals by 175.0% in the 4th quarter. Citigroup Inc. now owns 10,236 shares of the company’s stock valued at $71,000 after acquiring an additional 6,514 shares during the period.
Shares of NASDAQ SYRS traded up $0.33 during midday trading on Friday, reaching $7.87. 111,000 shares of the stock were exchanged, compared to its average volume of 249,803. The firm has a market cap of $320.43 million, a price-to-earnings ratio of -3.99 and a beta of 1.58. Syros Pharmaceuticals has a twelve month low of $4.45 and a twelve month high of $11.93. The firm has a 50-day simple moving average of $7.53 and a two-hundred day simple moving average of $7.68. The company has a quick ratio of 4.92, a current ratio of 4.92 and a debt-to-equity ratio of 0.20.
Syros Pharmaceuticals Company Profile
Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for cancer and monogenic diseases, and building a pipeline of gene control medicines. Its lead product candidates include SY-1425, a selective retinoic acid receptor alpha agonist, which is in a Phase II clinical trial for genomically defined subsets of patients with acute myeloid leukemia (AML) and myelodysplastic syndrome; SY-1365, a selective cyclin-dependent kinase 7 (CDK7) inhibitor, which is in a Phase I clinical trial that is used for treating patients with solid tumors and blood cancers, including ovarian and breast cancer; and SY-5609, a CDK7 inhibitor, which is in preclinical studies to treat oncology patients.
Read More: How to build a Fibonacci channel
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Syros Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.